RSV

The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.

Lung sound analysis was able to confirm airway narrowing in patients with respiratory syncytial virus (RSV) acute bronchiolitis.

Administering extended half-life respiratory syncytial virus (RSV) antibodies in the newborn nursery would minimize access disparities and ensure optimal uptake, study authors posited.

Palivizumab may be well tolerated and effective in the prevention of serious respiratory symptoms due to infection with respiratory syncytial virus (RSV).

A recent study found that most infants who required intensive care for respiratory syncytial virus (RSV) were healthy and born at term, indicating that preventive interventions for RSV must target all infants, according to the authors.

Results of a new review confirm an association between respiratory syncytial virus (RSV) and wheezing in infants.

A review identified specificities that suggested that infections of respiratory syncytial virus (RSV) evolve chest tomography features.

The oral respiratory syncytial virus (RSV) fusion protein inhibitor AK0529 was found to be well tolerated and reduced viral load in infants.

A study that analyzed pre- and postpandemic respiratory syncytial virus (RSV) seasons found that children and adults followed the same biannual pattern.

A study conducted in Colombia found that detection of respiratory syncytial virus (RSV) was associated with air pollutants, the health care system, and weather.

A study conducted in China found that respiratory syncytial virus (RSV) epidemic was seasonal and most often infected infants born 1 to 2 months before the start of the season.

Beyfortus, which can help prevent respiratory syncytial virus (RSV) in infants and toddlers, was approved by the FDA on July 17.

A study from Western Australia found that the influenza vaccine has a possible protective effect against hospitalization for respiratory syncytial virus (RSV).

Older adults and infants were found to have the highest mortality and hospitalization rates of respiratory syncytial virus (RSV).

In a recent study, immune-inflammatory index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were associated with infection of respiratory syncytial virus (RSV) in children.

Residents of homeless shelters were tested for respiratory syncytial virus (RSV) and influenza, which were found to have similar prevalence in the population.

Hospitalizations of infants in 4 middle-income countries were associated with respiratory syncytial virus (RSV) during the respiratory illness season.

The burden of respiratory syncytial virus (RSV) and the effect of vaccines could be affected by underestimation of RSV in older adults.

Respiratory syncytial virus (RSV) was detected easiest when using reverse transcription polymerase chain reaction (RT-PCR) tests in a pediatric population.

Nirsevimab was unanimously recommended by the FDA Advisory Committee for immunization against respiratory syncytial virus (RSV) in infants.

The Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Symptoms Scale demonstrated logical patterns of upper and lower respiratory symptoms among participants.

The sharp reduction in costs for hospitalization from respiratory syncytial virus (RSV) in infants 3 months and younger after the COVID-19 pandemic outweighed the cost increase for children aged 3 to 24 months.

Children were hospitalized most commonly due to respiratory syncytial virus (RSV) compared with influenza and COVID-19 during a season with respiratory pathogen cocirculation.

Although lack of routine testing and limitations to current diagnostic testing likely lead to underreporting of respiratory syncytial virus, RSV still poses a substantial economic burden.

The Biden administration said it will expand health care access, including mental health care, to students; depression reaches an all-time high in the United States; the FDA’s independent vaccine advisers are meeting to discuss the safety and effectiveness of a respiratory syncytial virus (RSV) vaccine.